AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital

NATICK, Mass., Oct. 7, 2021 -- (Healthcare Sales & Marketing Network) -- AffyImmune Therapeutics, Inc., a clinical stage biotechnology company developing and deploying its Tune & Track platform for the use of CAR T cells to treat solid tumors, announced t... Biopharmaceuticals, Venture Capital AffyImmune Therapeutics
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news